

Accepted Manuscript

Title: Neurobiology and neuropharmacology of monoaminergic systems
“Your article is registered as belonging to the Special Issue/Collection entitled “Monoamines”. If this is NOT correct and your article is a regular item or belongs to a different Special Issue please contact b.mutharasan@elsevier.com immediately prior to returning your corrections.”



Author: Philippe De Deurwaerdère

PII: S0301-0082(17)30022-9
DOI: <http://dx.doi.org/doi:10.1016/j.pneurobio.2017.02.001>
Reference: PRONEU 1480

To appear in: *Progress in Neurobiology*

Author: Rona R. Ramsay

PII: S0301-0082(17)30022-9
DOI: <http://dx.doi.org/doi:10.1016/j.pneurobio.2017.02.001>
Reference: PRONEU 1480

To appear in: *Progress in Neurobiology*

Author: Giuseppe Di Giovanni

PII: S0301-0082(17)30022-9
DOI: <http://dx.doi.org/doi:10.1016/j.pneurobio.2017.02.001>
Reference: PRONEU 1480

To appear in: *Progress in Neurobiology*

Please cite this article as: <http://dx.doi.org/>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

EDITORIAL OF THE SPECIAL ISSUE:**NEUROBIOLOGY AND NEUROPHARMACOLOGY OF MONOAMINERGIC SYSTEMS**

Philippe De Deurwaerdère^{a,*}, Rona R. Ramsay^{b,*}, Giuseppe Di Giovanni^{c,d,*}

¹*Centre National de la Recherche Scientifique (Unité Mixte de Recherche 5293) 33076 Bordeaux Cedex, France.*

²*Biomedical Sciences Research Centre, School of Biology, University of St Andrews, St Andrews, UK*

³*Department of Physiology & Biochemistry, Faculty of Medicine and Surgery, University of Malta*

⁴*Neuroscience Division, School of Biosciences, Cardiff University, Cardiff, UK*

***Corresponding authors:** Professor Philippe De Deurwaerdère email: deurwaer@u-bordeaux.fr, Dr

Rona R. Ramsay rrr@st-andrews.ac.uk and Professor Giuseppe Di Giovanni email:

giuseppe.digiovanni@um.edu.mt

Neuropharmacological journey in monoaminergic fields.

The extensive research conducted on monoaminergic systems including dopaminergic, serotonergic, noradrenergic, histaminergic and, to a lower extent melatonergic systems, continues to expand our current knowledge. The topic has enormous health, economic, scientific and conceptual stakes, with engagement across disciplines covering medicinal chemistry to neuropsychiatric and neurological diseases. This special issue presents scientific updates with in depth analyses on selected aspects of this complicated topic.

Antipsychotic and antidepressant drugs opened the way to intensive research on monoaminergic systems. The serendipitous discoveries of these treatments in the 1950s led to the identification of monoaminergic systems as the main origin of their efficacy. Under the scope of neurosciences and biological psychiatry, much fundamental research has identified the proteins involved in the function of monoaminergic systems. As illustrated on Figure 1, each monoamine can act on a variety of receptors distinctly expressed in the brain, and displaying some selectivity for each monoamine. While the picture roughly illustrates the main families of these receptors, molecular biology has revealed the existence of several subtypes for most of these receptors coming from alternative splicing, posttranscriptional and/or posttranslational processes. The identification of specific monoaminergic targets involved in the beneficial and side effects of these drugs has enabled medicinal chemistry to produce drugs favouring one or several good targets over the deleterious ones. The article by Butini et al is an illustration of the pharmacological profile and chemical requirements of new antipsychotic or anti-Parkinsonian drugs to achieve good efficacy with low or no side-effects (Butini *et al.*, 2017). Several receptors or enzymes are usually targeted leading to the new popularity of multitarget drug

design (Millan, 2009; Ramsay *et al.*, 2016; Weinreb *et al.*, 2016).

The pharmacological profile of a multi-target drug is even more complicated because the molecular environment of one target is specific to the cell expressing this target, leading to biased agonists. This means that a drug behaves differently on its target depending on the tissue. Interesting achievements have been obtained with drugs preferentially activating somatodendritic 5-HT_{1A} autoreceptors versus heteroreceptors and *vice versa* that could be pertinent for the treatment of mood disorders or dyskinesia induced by L-DOPA. While the specifications are growing for producing newer drugs, the molecular pharmacology becomes more insightful in conceptualizing the partnerships of neurotransmitter receptors in space and time. Wirth *et al.* report an interesting perspective of molecular signalling events in the morphogenic effects of serotonin (5-HT) (Wirth *et al.*, 2017). These effects include a variety of 5-HT receptors that modulate synaptogenesis, neurite outgrowth, dendritic spine shape and density. These regulations occur at different stages of the development, are region-dependent and could maintain aberrant modelling of networks and pathophysiology.

The refinement of pharmacological drugs has helped elucidate a better understanding of the pathophysiology of numerous CNS diseases. A better knowledge of pathophysiology is surely a step for the identification of new pharmacological targets, perhaps beyond the symptomatic treatment (Millan *et al.*, 2015). At a time where the *pathology-to-drug* discovery approach is in expansion, our certitudes regarding the treatment of Parkinson's disease and the mechanism of action of the lead antiparkinsonian treatment L-DOPA are disappearing. The metabolic precursor of dopamine (DA) L-DOPA is administered to patients soon after the identification of the loss of dopamine in the putamen and caudate nucleus of Parkinson patients. De Deurwaerdère *et al.* have reported numerous data dampening the idea that the benefit and side effects of L-DOPA were related to an increase in DA in the caudate nucleus and the putamen (De Deurwaerdere *et al.*, 2017). The mechanisms of L-DOPA appear to be much more subtle, widespread in the brain and distinct from dopaminergic agonists.

Referring again to Figure 1, it is noteworthy that monoaminergic systems share enzymes for their biosynthesis, the vesicular monoamine transporter for their translocation into the vesicles of exocytosis, enzymes for their catabolism as well transporters for the reuptake. Some transporters and enzymes are also present in neighbouring glial and neuronal cells. Consequently, the administration of amino acid precursors such as L-DOPA or drugs that act on degrading enzymes such as monoamine oxidase inhibitors can only result in ectopic effects.

Serendipity has played an important role in the development of drugs aimed at treating the symptoms of schizophrenia, mood disorders or Parkinson's disease. This point of view is further stressed in considering that diseases like Alzheimer's disease or epilepsy still do not have monoaminergic-based treatments (Di Giovanni *et al.*, 2016; Svob Strac *et al.*, 2016). The paper by Simic *et al.* recalls that Alzheimer's disease is also marked by several perturbations of monoaminergic systems (Simic *et al.*, 2017). Hopefully, the numerous clinical trials they report with monoaminergic drugs targeting neuroreceptors will end up soon in a more appropriate medical care of the disease. The other side of this thought is that it is often difficult to understand the role of monoaminergic systems in the benefit and side effects of efficacious therapies. Here, two articles by Faggiani and Benazzouz and by Galati *et al.*, focus on the impact of deep brain stimulation of the subthalamic nucleus in the treatment of Parkinson's disease with specific regards on monoamines and on non-motor and motor effects of the treatment, (Faggiani and Benazzouz, 2017; Stefani *et al.*, 2017), respectively. Numerous neurochemical effects are triggered by the deep brain stimulation of the subthalamic nucleus on monoaminergic systems but the extent to which these modifications lead to therapeutic effects is still a matter of debate.

At one point one may wonder why it is so difficult to progress and to understand the function of these systems. Maybe the organization and the morphology of these systems is a real issue. In fact, the cell bodies of these neurons are confined in hypothalamus (histamine), mesencephalon (DA, 5-HT),

pons (5-HT) or medulla (noradrenaline) and innervate widely the entire encephalon with thousand sites of release for only one neuron. The neurohumoral way of contacting neurobiological networks and long distance neurons imply local and distal interactions. In addition, the monoaminergic systems establish complex interactions in the brain. De Deurwaerdère and Di Giovanni emphasise the interaction between 5-HT and DA systems (De Deurwaerdere and Di Giovanni, 2017). Beyond the molecular and cellular complexity of the mechanisms involved in the influence of 5-HT on DA neuronal function, the authors highlight also the multiplicity of regions and dimensions implicated in this interaction, which is important for the mechanism of action of antipsychotic, antidepressant, anti-Parkinsonian and anti-addictive drugs.

While there has been a lot of progress in molecular pharmacology, it is also mandatory to progress on the physiological roles of these monoaminergic systems in the brain. The neuropharmacological approaches brought many indications and still will bring more. Lorincz and Adamantidis in this issue highlight the use of new technologies such as optogenetic targeting specifically subsets of neurons, systems or receptors to study the function of monoaminergic systems (Lorincz and Adamantidis, 2017). These new approaches will shed another light on monoaminergic systems to better understand the efficacy of various medicines used to treat CNS diseases.

The tale continues.

Acknowledgments

This Special Issue, and the collaboration among the researchers that contributed to it, was initiated by EU COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain”.

References

- Butini, S., Nikolic, K., Kassel, S., Bruckmann, H., Filipic, S., Agbaba, D., Gemma, S., Brogi, S., Brindisi, M., Campiani, G., Stark, H., 2017. Polypharmacology of dopamine receptor ligands. *Progress in neurobiology*.
- De Deurwaerdere, P., Di Giovanni, G., 2017. Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications. *Progress in neurobiology*.
- De Deurwaerdere, P., Di Giovanni, G., Millan, M.J., 2017. Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry. *Progress in neurobiology*.
- Di Giovanni, G., Svob Strac, D., Sole, M., Unzeta, M., Tipton, K.F., Muck-Seler, D., Bolea, I., Della Corte, L., Nikolac Perkovic, M., Pivac, N., Smolders, I.J., Stasiak, A., Fogel, W.A., De Deurwaerdere, P., 2016. Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases. *Frontiers in neuroscience* 10, 541.
- Faggiani, E., Benazzouz, A., 2017. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: From history to the interaction with the monoaminergic systems. *Progress in neurobiology*.
- Lorincz, M.L., Adamantidis, A.R., 2017. Monoaminergic control of brain states and sensory processing: Existing knowledge and recent insights obtained with optogenetics. *Progress in neurobiology*.
- Millan, M.J., 2009. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics* 6, 53-77.
- Millan, M.J., Goodwin, G.M., Meyer-Lindenberg, A., Ove Ogren, S., 2015. Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. *Eur Neuropsychopharmacol* 25, 599-656.
- Ramsay, R.R., Majekova, M., Medina, M., Valoti, M., 2016. Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration. *Frontiers in neuroscience* 10, 375.
- Simic, G., Babic Leko, M., Wray, S., Harrington, C.R., Delalle, I., Jovanov-Milosevic, N., Bazadona, D., Buee, L., de Silva, R., Di Giovanni, G., Wischik, C.M., Hof, P.R., 2017. Monoaminergic neuropathology in Alzheimer's disease. *Progress in neurobiology*.
- Stefani, A., Trendavilof, V., Liguori, C., Fedele, E., Galati, S., 2017. Subthalamic nucleus Deep Brain Stimulation on motor-symptoms of Parkinson's disease: focus on neurochemistry. *Progress in neurobiology*.
- Svob Strac, D., Pivac, N., Smolders, I.J., Fogel, W.A., De Deurwaerdere, P., Di Giovanni, G., 2016. Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs. *Frontiers in neuroscience* 10, 492.
- Weinreb, O., Amit, T., Bar-Am, O., Youdim, M.B., 2016. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and beta-amyloid in ageing and Alzheimer's disease. *Br J Pharmacol* 173, 2080-2094.
- Wirth, A., Holst, K., Ponimaskin, E., 2017. How serotonin receptors regulate morphogenic signalling in neurons. *Progress in neurobiology*.

LEGEND TO FIGURE 1

Molecular organization of central monoaminergic systems. The figure shows each monoamine system (dopamine, DA; noradrenaline, NA; serotonin, 5-HT; histamine); the biosynthesis, metabolism, the receptors and transporters. Colors are used to identify the proteins that are selective for each system while the black color is used for non-specific proteins. The terminals of each monoaminergic neurons contact post-synaptic elements in the brain that express a variety of receptors which are more or less specific for each monoamine. The main families are represented. Autoreceptors can be located at terminals and cell bodies for most monoaminergic systems. In the case of serotonergic cells, 5-HT_{1A} autoreceptors are addressed at cell bodies and 5-HT_{1B} autoreceptors are addressed at terminals; 5-HT_{2B} autoreceptors would be addressed at both sites. The post-synaptic elements (neurons, glial cells) also express enzymes involved in the metabolism of monoamines (MAO-A/B or COMT) as well as non-specific transporters. DBH is mainly expressed in vesicles of exocytosis in noradrenergic terminals. AADC, aromatic L-amino acid decarboxylase; DBH, dopamine β-hydroxylase; TPH, tryptophan hydroxylase; VMAT2, vesicular monoamine transporter; SERT, 5-HT transporter, DAT, DA transporter; NET, NA transporter; OCT, organic cation transporters; PMAT, plasma membrane monoamine transporter; HDC, L-histidine decarboxylase; MAO, monoamine oxidase (A or B); COMT, catechol-O-methyl transferase.

